World Government Summit: UAE Sets Global Framework for Governments to Prioritize Happiness as Key Measure of Progress & Development
With the World Health Organization expecting depression to rank in the top three biggest diseases within the next 15 years, over 300 global experts, scientists and decision makers met in Dubai today for the first Global Dialogue on Happiness.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170211005012/en/
The conference is a global initiative driven by the vision of His Highness Sheikh Mohammed Bin Rashid Al Maktoum, Vice President and Prime Minister of the UAE and Ruler of Dubai and intends to create a framework for governments to align their policies with the happiness and well-being of their people. To underscore its commitment to this initiative, the UAE has created an official cabinet-level position focused specifically on happiness.
The Global Dialogue on Happiness is a pre-event to the 2017 World Government Summit , beginning 12 February in Dubai.
UAE Minister of State for Happiness H.E. Ohood Bint Khalfan Al Roumi, outlined the sense of urgency and moral imperative of governments to take the well-being of their citizens seriously: “350 million people globally suffer depression and 800,000 people between the ages of 15-29 commit suicide annually.”
The UAE is tackling these concerns directly, convening global experts on happiness to build a framework to implement ideas that will potentially affect substantial positive change and build happiness in societies. According to findings from “A 75-Year Study on Human Happiness,” by Dr. Robert Waldinger, Harvard Professor of Clinical Psychology: “Close relationships were the strongest predictor of what kept people happy throughout their lives.”
Helen Clark, Administrator of the UNDP spoke about the Human Development Index and reinforced the need to measure happiness to accurately assess and compare progress across countries.
Prime Minister of Bhutan Tshering Tobgay spoke about his country’s Gross National Happiness initiative which considers responsibility of individual happiness in the same way it thinks about education, healthcare or any other public good. “Great philosophers and religious leaders have devoted their lives to teaching people how to be happy,” he said. “Why don’t governments make happiness a public good rather than relegating it to an individual pursuit?”
The 2017 World Government Summit features 150 speakers across 114 sessions that highlight the world’s most pressing challenges and showcase best practices and cutting-edge solutions to deal with them.
*Source: ME NewsWire
World Government Summit
Wael Hayatli, + 971559655728
Information om Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Følg pressemeddelelser fra Business Wire
Skrive dig op her og du vil løbende modtage pressemeddelelser på mail. Indtast din mail, klik på abonner og følg instruktionerne i den udsendte mail.
Flere pressemeddelelser fra Business Wire
ASTRAZENECA10.12.2017 23:47 | pressemeddelelse
AstraZeneca’s Calquence (acalabrutinib) Shows Potential in Chronic Lymphocytic Leukaemia Trials
NJ-CELGENE/BLUEBIRD-BIO10.12.2017 16:32 | pressemeddelelse
Celgene Corporation and bluebird bio Announce Updated Results from Ongoing Multicenter Phase 1 Study of bb2121 Anti-BCMA CAR T Cell Therapy in Patients with Late Stage Relapsed/Refractory Multiple Myeloma at ASH Annual Meeting
GA-GILEAD-SCIENCES/KITE10.12.2017 16:32 | pressemeddelelse
Kite Announces Long-Term Data From Pivotal ZUMA-1 Study of Yescarta™ (Axicabtagene Ciloleucel) in Patients With Refractory Large B-cell Lymphoma
MA-TAKEDA/SEATTLE10.12.2017 14:02 | pressemeddelelse
Takeda and Seattle Genetics to Present Positive Data from Phase 3 ECHELON-1 Clinical Trial Evaluating ADCETRIS® (brentuximab vedotin) in Frontline Advanced Hodgkin Lymphoma
ASTRAZENECA9.12.2017 19:02 | pressemeddelelse
AstraZeneca’s Calquence (acalabrutinib) Demonstrates Activity in Relapsed or Refractory Mantle Cell Lymphoma Trial
JANSSEN9.12.2017 18:21 | pressemeddelelse
Sustained Benefit in Patients with Relapsed/Refractory Mantle Cell Lymphoma Demonstrated by 3.5 Year Follow-up Data of Imbruvica®▼(ibrutinib)
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter, og finde vores kontaktoplysninger.Besøg vores nyhedsrum